Advancing evidence-generating medicine
Osmind’s research is helping to set new standards for mental health interventions and improve patient outcomes. See how we work with research partners to generate real-world evidence to accelerate advances in mental health care.
Selected research projects
Impact of duration of esketamine nasal spray treatment on change in depression symptoms in real-world patients
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Measurement Based Care Learning Lab
MacMillan (2024). American Psychiatric Association Annual Meeting.
Psychiatric Treatments that have FDA’s Breakthrough Therapy Status
MacMillan (2024). American Psychiatric Association Annual Meeting.
Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research
A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic
Hagai et al. (2024). Oxford Ketamine Conference.
Osmind Announces 2024 Community Advisory Board: Leading Mental Health Clinicians
Let's transform mental health together
Click here to learn more about our research or to discuss collaboration opportunities.
